Fatigue, quality of life and metabolic changes in men treated with first-line enzalutamide versus abiraterone plus prednisolone for metastatic castration-resistant prostate cancer (HEAT): a randomised trial protocol. [electronic resource]
Producer: 20200910Description: e030218 p. digitalISSN:- 2044-6055
- Androgen Antagonists -- adverse effects
- Androstenes -- adverse effects
- Antineoplastic Combined Chemotherapy Protocols -- adverse effects
- Benzamides
- Blood Glucose -- metabolism
- Clinical Trials, Phase III as Topic
- Denmark
- Fatigue -- chemically induced
- Humans
- Male
- Neoplasm Invasiveness -- pathology
- Neoplasm Staging
- Nitriles
- Phenylthiohydantoin -- adverse effects
- Prednisolone -- adverse effects
- Prostatic Neoplasms, Castration-Resistant -- drug therapy
- Quality of Life
- Randomized Controlled Trials as Topic
- Risk Assessment
- Survival Analysis
- Treatment Outcome
No physical items for this record
Publication Type: Clinical Trial Protocol; Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.